Latest Information Update: 23 May 1995
At a glance
- Originator Asahi Kasei
- Class Anti-inflammatories; Antiallergics; Antineoplastics; Radioprotectives
- Mechanism of Action Hyaluronidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Radioprotection
Most Recent Events
- 23 May 1995 Discontinued-Preclinical for Radiation injuries (Prevention)/Radioprotection in Japan (Unknown route)